WO2012068531A3 - Novel compositions and uses of anti-hypertension agents for cancer therapy - Google Patents
Novel compositions and uses of anti-hypertension agents for cancer therapy Download PDFInfo
- Publication number
- WO2012068531A3 WO2012068531A3 PCT/US2011/061510 US2011061510W WO2012068531A3 WO 2012068531 A3 WO2012068531 A3 WO 2012068531A3 US 2011061510 W US2011061510 W US 2011061510W WO 2012068531 A3 WO2012068531 A3 WO 2012068531A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer therapy
- novel compositions
- cancer
- compositions
- hypertension agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013127625/15A RU2013127625A (en) | 2010-11-18 | 2011-11-18 | NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY |
CN201180065389.2A CN103561726A (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
CA2817250A CA2817250A1 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
EP11841427.5A EP2640359A4 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
AU2011329638A AU2011329638C1 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
JP2013540082A JP2014505666A (en) | 2010-11-18 | 2011-11-18 | Antihypertensive composition and use for cancer treatment |
US13/834,094 US20130287688A1 (en) | 2010-11-18 | 2013-03-15 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41519210P | 2010-11-18 | 2010-11-18 | |
US61/415,192 | 2010-11-18 | ||
US201161438240P | 2011-01-31 | 2011-01-31 | |
US61/438,240 | 2011-01-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/834,094 Continuation-In-Part US20130287688A1 (en) | 2010-11-18 | 2013-03-15 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012068531A2 WO2012068531A2 (en) | 2012-05-24 |
WO2012068531A3 true WO2012068531A3 (en) | 2013-11-28 |
Family
ID=46084685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/061510 WO2012068531A2 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2640359A4 (en) |
JP (2) | JP2014505666A (en) |
CN (1) | CN103561726A (en) |
AU (1) | AU2011329638C1 (en) |
CA (1) | CA2817250A1 (en) |
RU (2) | RU2018102375A (en) |
WO (1) | WO2012068531A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4903036B2 (en) | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | Aprotinin and analogs as carriers that cross the blood brain barrier |
EP1907009A4 (en) | 2005-07-15 | 2009-09-02 | Angiochem Inc | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
DK2279008T3 (en) | 2008-04-18 | 2019-04-29 | Angiochem Inc | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED PROCEDURES FOR PREPARATION AND USE |
CN102245642A (en) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Conjugates of GLP-1 agonists and uses thereof |
RU2531591C2 (en) | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Etoposide and doxorubicin conjugates for drug delivery |
AU2009322043A1 (en) | 2008-12-05 | 2011-07-07 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
BRPI0922611A2 (en) | 2008-12-17 | 2018-11-06 | Angiochem Inc | type 1 membrane matrix metalloprotein inhibitors and uses thereof |
CA2759129C (en) | 2009-04-20 | 2018-12-11 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
WO2013155493A1 (en) | 2012-04-12 | 2013-10-17 | Yale University | Methods of treating inflammatory and autoimmune diseases and disorders |
AU2013259772A1 (en) * | 2012-05-07 | 2014-12-04 | Massachusetts Institute Of Technology | Novel compositions and uses of anti-hypertension agents for cancer therapy |
JP6218084B2 (en) | 2012-10-04 | 2017-10-25 | 国立研究開発法人国立循環器病研究センター | Medicament for inhibiting malignant tumor metastasis |
EA201590822A1 (en) * | 2012-11-02 | 2016-01-29 | Фармасайкликс, Инк. | ADJUVANT THERAPY INHIBITOR KINASE OF THE FAMILY TEC |
WO2014129914A1 (en) * | 2013-02-22 | 2014-08-28 | Auckland Uniservices Limited | Methods of treatment |
US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
EP2961483A4 (en) * | 2013-03-01 | 2017-03-08 | The Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
WO2014168191A1 (en) * | 2013-04-10 | 2014-10-16 | 公立大学法人奈良県立医科大学 | Prophylactic and/or therapeutic agent for hepatocellular carcinoma |
EP3062790B1 (en) * | 2013-11-01 | 2023-03-08 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
JP6845691B2 (en) * | 2013-11-01 | 2021-03-24 | イェール ユニバーシティーYale University | Regulatory particles for immunotherapy |
CA2983755A1 (en) * | 2015-04-25 | 2016-11-03 | The General Hospital Corporation | Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer |
DK3307326T3 (en) | 2015-06-15 | 2020-10-19 | Angiochem Inc | METHODS FOR THE TREATMENT OF LEPTOMENINGAL CARCINOMATOSIS |
CN105326812A (en) * | 2015-10-28 | 2016-02-17 | 南昌大学 | Sorafenib solid lipid nanoparticles and preparation method thereof |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
JP6956091B2 (en) * | 2016-08-26 | 2021-10-27 | 哲治 奥野 | Micronanologic agents and their use |
CA3038657A1 (en) * | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
CN108358995B (en) * | 2017-01-25 | 2021-07-06 | 四川大学 | CP-iRGD polypeptide, iDPP nanoparticle, drug-loaded compound and preparation method and application thereof |
RU2724398C1 (en) * | 2019-09-03 | 2020-06-23 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for determining aggressiveness of lung cancer |
US20230101687A1 (en) * | 2019-12-13 | 2023-03-30 | Massachusetts Institute Of Technology | Synthetic tissue barriers and uses thereof |
EP3842099A1 (en) | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Use of losartan for the treatment of fibrotic diseases, in particular epidermolysis bullosa |
CN114917345A (en) * | 2021-04-07 | 2022-08-19 | 北京蛋白质组研究中心 | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer |
CN115317627B (en) * | 2022-08-26 | 2023-10-24 | 江西中医药大学 | Application of ABT-510 peptide in preparation of tumor imaging agent |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010019715A1 (en) * | 1997-09-18 | 2001-09-06 | Idec Pharmaceuticals Corporation | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US20070129331A1 (en) * | 2004-04-20 | 2007-06-07 | Rnd Pharmaceuticals, Inc. | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives |
US20080063724A1 (en) * | 2005-02-18 | 2008-03-13 | Desai Neil P | Methods and compostions for treating proliferative diseases |
US20090012052A1 (en) * | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
US20090220588A1 (en) * | 2008-02-21 | 2009-09-03 | Massachusetts Institute Of Technology | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ATE196606T1 (en) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA |
US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
DE10144980B4 (en) | 2001-09-12 | 2004-06-03 | Webasto Vehicle Systems International Gmbh | Guide device for a lid of a vehicle roof to be opened |
WO2006014626A2 (en) | 2004-07-19 | 2006-02-09 | Celator Pharmaceuticals, Inc. | Partuculate constructs for release of active agents |
TWI386225B (en) | 2004-12-23 | 2013-02-21 | Alcon Inc | Rnai inhibition of ctgf for treatment of ocular disorders |
TW200637539A (en) | 2005-01-20 | 2006-11-01 | Shionogi & Co | CTGF inhibitors |
PL3520815T3 (en) | 2005-02-08 | 2022-04-11 | Genzyme Corporation | Antibodies to tgfbeta |
US7846908B2 (en) | 2006-03-16 | 2010-12-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of TGF-beta and therapeutic uses thereof |
WO2010005721A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
ES2654533T3 (en) | 2008-06-16 | 2018-02-14 | Pfizer Inc. | Procedures for the preparation of functionalized diblock copolymers with a targeting agent for use in the manufacture of therapeutic nanoparticles |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
DE102009002623A1 (en) | 2009-04-24 | 2010-11-04 | BSH Bosch und Siemens Hausgeräte GmbH | Program selector for a domestic appliance, in particular for a washing machine |
-
2011
- 2011-11-18 WO PCT/US2011/061510 patent/WO2012068531A2/en active Application Filing
- 2011-11-18 CA CA2817250A patent/CA2817250A1/en not_active Abandoned
- 2011-11-18 RU RU2018102375A patent/RU2018102375A/en not_active Application Discontinuation
- 2011-11-18 EP EP11841427.5A patent/EP2640359A4/en not_active Withdrawn
- 2011-11-18 RU RU2013127625/15A patent/RU2013127625A/en not_active Application Discontinuation
- 2011-11-18 JP JP2013540082A patent/JP2014505666A/en not_active Withdrawn
- 2011-11-18 CN CN201180065389.2A patent/CN103561726A/en active Pending
- 2011-11-18 AU AU2011329638A patent/AU2011329638C1/en not_active Ceased
-
2017
- 2017-02-06 JP JP2017019388A patent/JP2017101056A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010019715A1 (en) * | 1997-09-18 | 2001-09-06 | Idec Pharmaceuticals Corporation | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US20070129331A1 (en) * | 2004-04-20 | 2007-06-07 | Rnd Pharmaceuticals, Inc. | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives |
US20080063724A1 (en) * | 2005-02-18 | 2008-03-13 | Desai Neil P | Methods and compostions for treating proliferative diseases |
US20090012052A1 (en) * | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
US20090220588A1 (en) * | 2008-02-21 | 2009-09-03 | Massachusetts Institute Of Technology | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
Non-Patent Citations (1)
Title |
---|
See also references of EP2640359A4 * |
Also Published As
Publication number | Publication date |
---|---|
CA2817250A1 (en) | 2012-05-24 |
EP2640359A2 (en) | 2013-09-25 |
JP2017101056A (en) | 2017-06-08 |
AU2011329638B2 (en) | 2016-10-13 |
JP2014505666A (en) | 2014-03-06 |
WO2012068531A2 (en) | 2012-05-24 |
CN103561726A (en) | 2014-02-05 |
EP2640359A4 (en) | 2015-11-04 |
AU2011329638A1 (en) | 2013-05-30 |
RU2018102375A (en) | 2019-02-21 |
RU2013127625A (en) | 2014-12-27 |
AU2011329638C1 (en) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012068531A3 (en) | Novel compositions and uses of anti-hypertension agents for cancer therapy | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
MX342951B (en) | Therapeutically active compositions and their method of use. | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
EP4140487A8 (en) | Combination therapy for treating cancer | |
WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
WO2012009406A3 (en) | Gold particles and methods of making and using the same in cancer treatment | |
EP2294184A4 (en) | Treatment of eye diseases and excessive neovascularization using a combined therapy | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
WO2011050302A3 (en) | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment | |
MX358491B (en) | A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate. | |
MX2014002171A (en) | Combination treatments for hepatitis c. | |
WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
MD20140123A2 (en) | Optimised subcutaneous therapeutic agents | |
WO2013134407A3 (en) | Procaspase 3 activation by combination therapy | |
WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
GB201213267D0 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
WO2012040331A3 (en) | Multistage nanoparticles | |
IN2015DN01328A (en) | ||
MX2015002573A (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell. | |
WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11841427 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2817250 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013540082 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011329638 Country of ref document: AU Date of ref document: 20111118 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011841427 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013127625 Country of ref document: RU Kind code of ref document: A |